SOUTH SAN FRANCISCO, Calif., July 19 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE) today announced that Stephen A. Sherwin, M.D.,
chairman and chief executive officer and Sharon E. Tetlow, chief financial
officer of Cell Genesys, will host a quarterly conference call relating to the
company's second quarter financial results that will be broadcast live over
the internet on Tuesday, July 26, 2005, at 8:30 a.m. PDT.
The webcast will be available on the investor relations section of the
company's website, http://www.cellgenesys.com. If you are unable to listen to the
live webcast, the call will be archived on the website for at least 48 hours
following the call. To access the replay, go to the Investor Relations
section of the website.
Cell Genesys is focused on the development and commercialization of novel
biological therapies for patients with cancer. The company is currently
pursuing two clinical stage product platforms -- GVAX(R) cancer vaccines and
oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of
GVAX(R) vaccine for prostate cancer, Phase 2 trials of GVAX(R) vaccines for
leukemia and pancreatic cancer, and a Phase 1 trial of CG0070 oncolytic virus
therapy for bladder cancer and potentially other types of cancer. Cell
Genesys continues to hold equity interests in its two former
subsidiaries -- Abgenix, Inc., an antibody products company and Ceregene,
Inc., which is developing gene therapies for neurodegenerative disorders.
Cell Genesys is headquartered in South San Francisco, CA and has its principal
manufacturing operation in Hayward, CA. For additional information, please
visit the company's website at http://www.cellgenesys.com.
Statements made herein about the company and its subsidiaries, other than
statements of historical fact, including statements about the company's
progress, results and timing of clinical trials and preclinical programs and
the nature of product pipelines are forward-looking statements and are subject
to a number of uncertainties that could cause actual results to differ
materially from the statements made, including risks associated with the
success of clinical trials and research and development programs, the
regulatory approval process for clinical trials, competitive technologies and
products, patents, continuation of corporate partnerships and the need for
additional financings. For information about these and other risks which may
affect Cell Genesys, please see the company's Annual Report on Form 10-K for
the year ended December 31, 2004 dated March 14, 2005 as well as Cell Genesys'
reports on Form 10-Q and 8-K and other reports filed from time to time with
the Securities and Exchange Commission. The company assumes no obligation to
update the forward-looking information in this press release.
CONTACT: Ina Cu, Investor Relations of Cell Genesys, Inc.,
+1-650-266-3200.
SOURCE Cell Genesys, Inc.
 back to top
Related links:
http://www.cellgenesys.com
CONTACT:
Ina Cu, Investor Relations of Cell Genesys,
Inc., +1-650-266-3200
|
